INTRODUCTION
Financial relationships between physicians and prescription drug or medical device manufacturers remain controversial. Recent large national studies have shown such relationships are associated with prescription of brand-name drugs, especially those sold by the sponsoring manufacturer, over equally effective lower-cost generics. 1, 2 Since 2013, industry payments and gifts are being publicly reported. Also, some large academic medical centers, physician employers, such as Kaiser Permanente, and states have banned or restricted detailing visits, physician payments, or gifts, and some manufacturers have changed their own practices for certain gifts. 3 We conducted a national survey of internal medicine physicians to assess how their financial relationships with industry have changed in this context.
METHODS
We randomly sampled 500 clinically active internists and 1000 internal medicine specialists (500 endocrinologists, 500 cardiologists) from the American Board of Internal Medicine's diplomate list; 84 lacked contact information. We asked 10 yes/no questions about Bdrug, device, or other medically related company^interactions in the last year: food inside or outside the workplace; free drug samples; pens, notepads, Tshirts; honoraria for speaking; payment for consulting services; payment for service on an advisory board; costs of personal expenses for attending meetings; free tickets to events; subsidized admission to meetings; or conferences for which Continuing Medical Education (CME) credits were awarded. To compare ties by physician characteristics, we used Pearson's chi-square test for categorical variables and two-sample t tests for continuous variables. All statistical analyses were performed using SAS 9.4 software (SAS Institute, NC). The Dartmouth College IRB approved the project.
RESULTS
We received 686 surveys (48% response rate). Respondents averaged 44 years old (SD 8)-13 years (SD 8) out of residency-and were 59% male, 72% specialist, and 56% Caucasian (4% Hispanic, 34% Asian, 3% African-American, and 4% other). About three-quarters (72%) reported any financial tie to industry. The most common benefits received were free drug samples (55%) and food or beverage in (48%) and outside (30%) the workplace. Fewer physicians reported receiving small gifts (8%) or payments for consulting (4%) or service on a scientific advisory board (3%).
In 2017, specialists reported more meals than internists (at work, 61% for cardiologists and 53% for endocrinologists vs. (Table 1) ). Specialists and older physicians generally reported more expertise-related payments (honoraria for speaking, consulting services, scientific advisory boards). These differences were similar to those found in a national physician survey in 2009 with similar questions and response rates. 4 Compared to 2009, fewer internal medicine physicians reported receiving all types of financial payments, with the greatest decrements related to food/beverage or tickets to sporting or cultural events (75% vs 42%) and speakers bureaus/consulting/advisory boards (18% vs 2%) ( Table 2) . Among cardiology specialists, the only significant differences were for drug samples (82% vs 60%) and speakers bureaus/ consulting/advisory boards (33% vs 8%).
DISCUSSION
While financial industry ties have fallen over the past 15 years, a majority of US physicians still reported them in 2017, most prominently, free samples and meals, the latter of which are usually provided during promotional communications related to a brand-name drug or medical device. Free samples are used as a marketing tool 5 and have been linked to prescribing of high-cost brand-name drugs over lower-cost generic alternatives. Our study is limited by non-response and possible underreporting of ties, as physicians may be reluctant to acknowledge industry ties given heightened scrutiny. The decline in financial ties may reflect successful regulation by states, academic institutions, and large employers, as well as consolidation of more physician practices under these entities, or a consequence of mandatory disclosure under the Sunshine Act. Yet financial connections between physicians and industry remain a prevalent force affecting prescribing practices and health care costs.
